logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Aslan Pharmaceuticals: A Small Firm with Early, Promising Results for Atopic Dermatitis

Aslan Pharmaceuticals  Aslan Pharmaceuticals ( ASLN ) is a clinical-stage immunology company announced positive interim unblinded data from three dose cohorts of its ongoing randomized, double-blind placebo-controlled multiple ascending dose study of ASLAN-004 for moderate to severe atopic dermatitis.  ...

Read More

March 1, 2021

0

Exelixis and Daiichi Sankyo: Preventing and Treating Diabetic Nephropathy

Exelixis and Daiichi Sankyo Partner to Prevent and Treat Diabetic Nephropathy Exelixis ( EXEL ) and Daiichi Sankyo ( DSNKY )  reported positive results from a phase 3 pivotal trial of esaxerenone , a product of the companies’ prior research...

Read More

November 8, 2019

0

The Reasons Why Ovid Therapeutics' Stock Outperformed Today

Ovid Therapeutics & Takeda Announce Agreement for Soticlestat Ovid Pharmaceuticals is eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales Potential first-in-class therapy reduced...

Read More

March 3, 2021

0

A First in Class Antibody for a Difficult to Treat Stomach Cancer and Maybe Others

Five Prime Therapeutics Antibody Plus Chemotherapy for Stomach Cancer Five Prime Therapeutics ( FPRX )  announced positive topline results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial compared mFOLFOX6 chemotherapy in combination with bemarituzumab ( bema, FPA144 ) - a first-in-class...

Read More

November 11, 2020

0

Another Approval from Canada for Exelixis Product CABOMETYX®(cabozantinib)

Exelixis and Ipsen Received Approval from Health Canada for CABOMETYX® From Exelixis ( EXEL )  we learned that its partner,  Ipsen Biopharmaceuticals Canada , has received approval from Health Canada of CABOMETYX®  (cabozantinib) tablets for the treatment of hepatocellular carcinoma (...

Read More

November 12, 2019

0

Reata Pharmaceuticals: A Successful Treatment for Alport Syndrome

Reata Pharmaceuticals CARDINAL Study Met Primary and Key Secondary Endpoints Reata Pharmaceuticals ( RETA ) announced that the Phase 3 portion of the CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease ( CKD ) caused by...

Read More

November 13, 2019

0

PTC Therapeutics' Product Risdiplam Met Trial Endpoints for the Treatment of Spinal Muscular Atrophy

PTC Therapeutics Risdiplam Results for SMA PTC Therapeutics ( PTCT ) has positive results from part 2 of the SUNFISH trial evaluating the safety and efficacy of the product risdiplam . The results demonstrate that the trial has met its...

Read More

November 14, 2019

0

Inovio to Proceed with Phase 2 Trial of INO-4800 Vaccine Candidate for COVID-19

Inovio Announced FDA Clearance to Proceed with Trial for COVID-19 Vaccine Candidate Inovio ( INO ) announced the receipt of the U.S. FDA clearance to proceed with the Phase 2 segment of its planned Phase 2/3 clinical trial for INO-4800,...

Read More

November 16, 2020

0

bluebird bio Provides Updated Findings of AML in LentiGlobin for SCD Gene Therapy Program

Updated Findings from bluebird bio bluebird bio analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in a clinical study of LentiGlobin for SCD bluebird bio initiated a process with regulators to resume clinical studies bluebird bio (...

Read More

March 10, 2021

0

Vir Biotechnology and GlaxoSmithKline: Independent Data Monitoring Committee Recommends Stopping Phase 3 COMET-ICE Trial Early

Vir Biotechnology and GlaxoSmithKline Recommended to Stop Phase 3 COMET-ICE Trial Vir Biotechnology ( VIR ) and GlaxoSmithKline ( GSK ) announced that an Independent Data Monitoring Committee ( IDMC ) recommended that the Phase 3 COMET-ICE trial - the...

Read More

March 11, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 106
  • 107
  • 108
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy